Traynor Capital Management Inc. lifted its position in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 2.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,727 shares of the company’s stock after acquiring an additional 194 shares during the period. Traynor Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $798,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Bromfield Sneider Wealth Advisors acquired a new stake in shares of Merck & Co., Inc. during the first quarter worth $79,000. ACG Wealth raised its stake in Merck & Co., Inc. by 5.6% during the first quarter. ACG Wealth now owns 13,523 shares of the company’s stock worth $1,110,000 after acquiring an additional 722 shares during the period. WealthBridge Investment Counsel Inc. raised its stake in Merck & Co., Inc. by 4.1% during the first quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company’s stock worth $7,206,000 after acquiring an additional 3,475 shares during the period. Captrust Financial Advisors lifted its holdings in Merck & Co., Inc. by 3.8% in the third quarter. Captrust Financial Advisors now owns 300,309 shares of the company’s stock worth $22,756,000 after acquiring an additional 11,068 shares during the last quarter. Finally, Beech Hill Advisors Inc. boosted its stake in Merck & Co., Inc. by 0.8% in the fourth quarter. Beech Hill Advisors Inc. now owns 77,934 shares of the company’s stock valued at $5,973,000 after acquiring an additional 581 shares during the period. 72.88% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have weighed in on MRK shares. Mizuho initiated coverage on Merck & Co., Inc. in a research report on Friday, April 1st. They issued a “buy” rating and a $100.00 target price on the stock. Barclays lifted their price objective on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. Morgan Stanley decreased their target price on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. SVB Leerink reiterated an “outperform” rating and set a $102.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, June 6th. Finally, StockNews.com initiated coverage on Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $91.60.
Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.81 by $0.33. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 47.86%. The firm had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. During the same quarter in the previous year, the business posted $1.40 earnings per share. The firm’s quarterly revenue was up 31.6% compared to the same quarter last year. As a group, equities research analysts forecast that Merck & Co., Inc. will post 7.32 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 8th. Stockholders of record on Wednesday, June 15th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, June 14th. Merck & Co., Inc.’s dividend payout ratio is 49.37%.
Merck & Co., Inc. Company Profile (Get Rating)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.